摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(1-t-butoxycarbonyl-2-hydroxymethylpiperidin-4-yl)-2H-isoquinolin-1-one | 680223-93-2

中文名称
——
中文别名
——
英文名称
3-(1-t-butoxycarbonyl-2-hydroxymethylpiperidin-4-yl)-2H-isoquinolin-1-one
英文别名
tert-butyl 2-(hydroxymethyl)-4-(1-oxo-2H-isoquinolin-3-yl)piperidine-1-carboxylate
3-(1-t-butoxycarbonyl-2-hydroxymethylpiperidin-4-yl)-2H-isoquinolin-1-one化学式
CAS
680223-93-2
化学式
C20H26N2O4
mdl
——
分子量
358.437
InChiKey
JKRIYBKSOQTSJX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    571.5±50.0 °C(Predicted)
  • 密度:
    1.206±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    78.9
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    3-(1-t-butoxycarbonyl-2-hydroxymethylpiperidin-4-yl)-2H-isoquinolin-1-one 、 ethyl acetate hydrochloride 在 乙醚 作用下, 以 乙酸乙酯 为溶剂, 反应 6.5h, 以to give 3-(2-hydroxymethylpiperidin-4-yl)-2H-isoquinolin-1-one hydrochloride (433 mg)的产率得到3-(2-hydroxymethylpiperidin-4-yl)-2H-isoquinolin-1-one hydrochloride
    参考文献:
    名称:
    Isoquinoline compound and pharmaceutical use thereof
    摘要:
    本发明涉及以下式(I)所表示的异喹啉化合物,其光学活性形式,其药学上可接受的盐,其水加合物,其水合物和溶剂合物,以及含有该化合物的用于预防和/或治疗由多聚(ADP-核糖基)聚合酶超反应性引起的疾病的药剂,以及含有该化合物的多聚(ADP-核糖基)聚合酶抑制剂。此外,该化合物可用作预防和/或治疗脑梗死的药剂,特别是作为急性脑梗死的预防和/或治疗药剂。此外,该化合物可用作改善与脑梗死相关的神经症状的预防和/或治疗药剂,特别是急性脑梗死的预防和/或治疗药剂。其中符号与描述中定义的相同。
    公开号:
    US07220759B2
点击查看最新优质反应信息

文献信息

  • Isoquinoline compound and pharmaceutical use thereof
    申请人:Mitsubishi Pharma Corporation
    公开号:US20040248931A1
    公开(公告)日:2004-12-09
    The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. 1 wherein the symbols are the same as defined in the description.
    本发明涉及一种异喹啉化合物,其由以下通式(I)表示,包括其光学活性形式、药学上可接受的盐、水合物、水合物和溶剂合物,以及用于预防和/或治疗由聚(ADP-核糖)聚合酶过度反应性引起的疾病的药物组合物,包含该化合物,以及包含该化合物的聚(ADP-核糖)聚合酶抑制剂。此外,该化合物可作为预防和/或治疗脑梗塞,特别是急性脑梗塞的药物。此外,该化合物可作为改善与脑梗塞,特别是急性脑梗塞相关的神经症状的预防和/或治疗药物。其中,符号的定义与说明书中的定义相同。
  • ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF
    申请人:Fujio Masakazu
    公开号:US20070161620A1
    公开(公告)日:2007-07-12
    The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.
    本发明涉及以下式(I)所表示的异喹啉化合物,其手性活性形式,其药学上可接受的盐,其水加合物,其水合物和其溶剂化物,以及包含该化合物的用于预防和/或治疗由多聚(ADP-核糖)聚合酶过度反应所致疾病的药剂和包含该化合物的多聚(ADP-核糖)聚合酶抑制剂。此外,该化合物可用作预防和/或治疗脑梗死的药剂,特别是作为预防和/或治疗急性脑梗死的药剂。此外,该化合物可用作改善与脑梗死相关的神经症状的预防性和/或治疗性药剂,特别是急性脑梗死。其中符号与描述中定义的相同。
  • ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF
    申请人:Mitsubishi Pharma Corporation
    公开号:EP1557414A1
    公开(公告)日:2005-07-27
    The present invention relates to an isoquinoline compound represented by the following formula (1), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction.
    本发明涉及下式(1)代表的异喹啉化合物、其光学活性形式、其药学上可接受的盐、其水加合物、其水合物和其溶解物,以及含有该化合物的预防和/或治疗由聚(ADP-核糖)聚合酶高反应性引起的疾病的制剂和含有该化合物的聚(ADP-核糖)聚合酶抑制剂。此外,该化合物还可作为预防和/或治疗脑梗塞的药物,特别是作为预防和/或治疗急性脑梗塞的药物。此外,该化合物还可作为预防和/或治疗剂,改善与脑梗塞,尤其是急性脑梗塞相关的神经症状。
  • US7220759B2
    申请人:——
    公开号:US7220759B2
    公开(公告)日:2007-05-22
  • US7459465B2
    申请人:——
    公开号:US7459465B2
    公开(公告)日:2008-12-02
查看更多